Search results for: Health Care Systems
Filter search results
Assessing Value, Budget Impact, and Affordability in Asia
10 July 2017
…and payer systems in Asian countries; pharmaceutical and medical device companies with interest and expertise in Asia; invited experts; and the organisers. The paper reports that: All systems consider health…
Can a Strong Economic Case Be Made for Investing in the NHS?
1 January 2019
…ministries and some sections of the media – that health systems such as… Debate about funding has highlighted the difficulty of persuading sceptics that the NHS is a good use…
The Trump Administration’s US Drug Pricing Proposal – What will happen next?
12 June 2025
…have negative effects on patients health and health systems sustainability on top of the delays. The gap between list and net price can be substantial, and exists in the US…
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
…its location. While promising for patients, healthcare systems are facing major challenges with… A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the…
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022, 2:00pm
…to the most effective treatments. Payers have accountability for enabling access within the context of the resources and treatment options that are available today. Health care systems more broadly strive…
Prof Devlin Elected Chair of EuroQol Group
25 November 2010
…health care systems in dozens of countries. EuroQol Group members include leading researchers from around the world with expertise in a range of fields, including health economics, psychology and various clinical…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel, global antibiotic development pipelines…
Valuing Orphan Medicines Using Multi-Criteria Decision Analysis
7 May 2013
…that must be made in coverage decisions. In all health care systems, HTA and reimbursement decisions begin with an assessment of value. Many systems take a distinct approach where orphan…
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
…systems worldwide are creating changes in the evidence required for both regulatory approval and reimbursement. Changes in the clinical and economic milieu of health care systems worldwide are creating changes…